Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Humacyte (NASDAQ:HUMA) and maintained a $6 price target.

August 31, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Humacyte, maintaining a $6 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Humacyte. The maintained price target of $6 also suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100